RT Journal Article
SR Electronic
T1 Dr. Balevic, <em>et al</em>, reply
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.200681
DO 10.3899/jrheum.200681
A1 Stephen J.  Balevic
A1 Christoph P.  Hornik
A1 Thomas P.  Green
A1 Megan E.B.  Clowse
A1 Daniel Gonzalez
A1 Anil R.  Maharaj
A1 Laura E.  Schanberg
A1 Amanda M.  Eudy
A1 Geeta K.  Swamy
A1 Brenna L.  Hughes
A1 Michael Cohen-Wolkowiez
YR 2020
UL http://www.jrheum.org/content/early/2020/05/20/jrheum.200681.abstract
AB We read with great interest the very thoughtful commentary by Drs. Joob and Wiwanitkit. We agree with the authors that, despite conflicting clinical data to date, it is possible that HCQ may have a protective effect in the setting of COVID-19. More importantly, we agree that optimal HCQ dosage and timing is a critical underpinning for clinical trials. However, we highlight several considerations regarding treatment with high dose HCQ.